Krystal Biotech, Inc. (BIT:1KRYS)
Italy · Delayed Price · Currency is EUR | Market Cap | 7.42B +119.2% |
| Revenue (ttm) | 361.93M +25.1% |
| Net Income | 195.17M +81.5% |
| EPS | 6.48 +79.7% |
| Shares Out | n/a |
| PE Ratio | 38.04 |
| Forward PE | 30.90 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 11 |
| Open | 271.30 |
| Previous Close | 256.00 |
| Day's Range | 259.00 - 271.30 |
| 52-Week Range | 110.10 - 271.30 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | May 4, 2026 |
About Krystal Biotech
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB803 for ocular complications of dystrophic epidermolysis bullosa; KB801 for neurotrophic keratitis; KB407, which is in Phase 1 clinical trials for treating cystic fibrosis; KB111 for Hailey... [Read more]
Financial Performance
In 2025, Krystal Biotech's revenue was $389.13 million, an increase of 33.94% compared to the previous year's $290.52 million. Earnings were $204.83 million, an increase of 129.74%.
Financial numbers in USD Financial StatementsNews
Corbus Pharmaceuticals Announces the Appointment of Nishant Saxena as Chief Business Officer and Schedules a Pre-2026 ASCO CRB-701 Data Conference Call
NORWOOD, Mass., May 21, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (Nasdaq: CRBP), a clinical-stage company focused on developing promising new therapies in oncology and obesity, t...
Krystal Biotech Slides: Corporate presentation
Krystal Biotech has posted slides in relation to its latest quarterly earnings report, which was published on May 20, 2026.
Krystal Biotech announces UK MHRA approval of Vyjuvek
Krystal Biotech (KRYS) announced that the United Kingdom Medicines and Healthcare products Regulatory Agency, or MHRA, granted marketing authorization to Vyjuvek for the treatment of wounds in patient...
Krystal Biotech Announces United Kingdom MHRA Approval of VYJUVEK® for the Treatment of Dystrophic Epidermolysis Bullosa
VYJUVEK approved for the treatment of DEB from birth with flexible administration options similar to those already granted in the United States, European Union, and Japan VYJUVEK is the first genetic...
Krystal Biotech Transcript: AGM 2026
The meeting covered director elections, auditor ratification, and compensation approvals, with all proposals passing. A brief Q&A followed the formal business, and final voting results will be filed with the SEC.
U.K.’s MHRA approves Krystal’s Vyjuvek for dystrophic epidermolysis bullosa
The Medicines and Healthcare products Regulatory Agency has approved Krystal Biotech’s (KRYS) beremagene geperpavec — Vyjuvek — for the treatment of wounds in patients with dystrophic epidermolysis bu...
Krystal Biotech Transcript: Bank of America Global Healthcare Conference 2026
Strong financial performance continues with high gross margins and expanding global launches, particularly in Europe and Japan. Pipeline progress includes fully enrolled ocular DEB and neurotrophic keratitis studies, and a cystic fibrosis program advancing toward pivotal trials.
Krystal Biotech to Present at BofA Securities 2026 Health Care Conference
PITTSBURGH, May 07, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) today announced that the Company will participate in the BofA Securities 2026 Health Care Conference o...
Krystal Biotech price target raised to $300 from $295 at Evercore ISI
Evercore ISI raised the firm’s price target on Krystal Biotech (KRYS) to $300 from $295 and keeps an Outperform rating on the shares.
Krystal Biotech price target raised to $378 from $371 at Citi
Citi raised the firm’s price target on Krystal Biotech (KRYS) to $378 from $371 and keeps a Buy rating on the shares.
Krystal Biotech price target lowered to $311 from $338 at Clear Street
Clear Street lowered the firm’s price target on Krystal Biotech (KRYS) to $311 from $338 and keeps a Buy rating on the shares after the company’s Q1 report and business…
Krystal Biotech Earnings Call Transcript: Q1 2026
Q1 2026 saw 32% year-over-year revenue growth to $116.4M, with strong VYJUVEK performance in the U.S., Europe, and Japan, 95% gross margin, and net income of $55.9M. Six clinical data readouts, including two registrational studies, are expected before year-end.
Krystal Biotech Earnings release: Q1 2026
Krystal Biotech released its Q1 2026 earnings on May 4, 2026, summarizing the period's financial results.
Krystal Biotech Quarterly report: Q1 2026
Krystal Biotech has published its Q1 2026 quarterly earnings report on May 4, 2026.
Krystal Biotech Slides: Q1 2026
Krystal Biotech has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 4, 2026.
Krystal Biotech sees FY26 R&D and SG&A expense $175M-$195M
07:06 EDT Krystal Biotech (KRYS) sees FY26 R&D and SG&A expense $175M-$195M
Krystal Biotech reports Q1 EPS $1.83, consensus $1.42
Reports Q1 revenue $116.36M, consensus $112.13M. “Following a successful 2025, we are entering 2026 with strong momentum, including two potential registrational study readouts and continued global exp...
Krystal Biotech Announces First Quarter 2026 Financial and Operating Results
$116.4 million in 1Q VYJUVEK global revenue and $846.7 million since launch Enrollment complete in KB803 (corneal abrasions in DEB patients) registrational study On track for KB803 and KB801 (NK) regi...
Krystal Biotech to Present at Upcoming Scientific Conferences
PITTSBURGH, April 30, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) announced today that the Company will be presenting on multiple programs at upcoming scientific conf...
Krystal Biotech to Report First Quarter 2026 Financial Results on May 4, 2026
PITTSBURGH, April 21, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) announced today that it will report its first quarter 2026 financial results on Monday, May 4, 2026,...
Krystal Biotech Proxy statement: Proxy filing
Krystal Biotech filed a proxy statement on April 3, 2026, providing details for shareholder voting and corporate governance matters.
Krystal Biotech Proxy statement: Proxy filing
Krystal Biotech filed a proxy statement on April 3, 2026, providing details for shareholder voting and corporate governance matters.
Krystal Biotech initiated with a Peer Perform at Wolfe Research
Wolfe Research initiated coverage of Krystal Biotech (KRYS) with a Peer Perform rating and no price target Krystal is “performing well” commercially with Vyjuvek and the firm thinks shares are…
Krystal Biotech price target raised to $325 from $318 at BofA
BofA raised the firm’s price target on Krystal Biotech (KRYS) to $325 from $318 and keeps a Buy rating on the shares. The firm increased Vyjuvek expectations, removed KB104 and…
Krystal Biotech Slides: Corporate presentation
Krystal Biotech has posted slides in relation to its latest quarterly earnings report, which was published on March 4, 2026.